Rao Nanquan, Wang Xiaotong, Zhai Yue, Li Jingzhi, Xie Jing, Zhao Yuming, Ge Lihong
1Department of Pediatric Dentistry, Peking University School and Hospital of Stomatology, 22 Zhongguancun Avenue South, Haidian District, Beijing, 100081 People's Republic of China.
2Department of Oral Emergency Department, Peking University School and Hospital of Stomatology, 22 Zhongguancun Avenue South, Haidian District, Beijing, 100081 People's Republic of China.
Diabetol Metab Syndr. 2019 Feb 28;11:22. doi: 10.1186/s13098-019-0417-y. eCollection 2019.
By 2030, diabetes mellitus (DM) will be the 7th leading cause of death worldwide. Type 2 DM (T2DM) is the most common type of DM and is characterized by insulin resistance and defective β-cell secretory function. Stem cells from human exfoliated deciduous teeth (SHED) are favorable seed cells for mesenchymal stem cells (MSCs)-based therapy due to their higher proliferation rates and easier access to retrieval. Currently, no study has revealed the therapeutic efficiency of MSCs for T2DM in Goto-Kakizaki (GK) rats. Hence, we aimed to explore the effect of SHED on T2DM in GK rats.
We investigated the effects of SHED on the progression of T2DM in GK rats. SHED and bone marrow mesenchymal stem cells (BMSCs) were injected via the tail vein. Body weight, fasting blood glucose and non-fasting blood glucose were measured before and after administration. At 8 weeks after injection, intraperitoneal insulin tolerance tests (IPITTs) and insulin release tests (IRTs) were performed. Additionally, hematoxylin-eosin (HE) staining, periodic acid-Schiff (PAS) staining and double-label immunofluorescence staining were used to explore the pathological changes in pancreatic islets and the liver. Immunohistochemistry (IHC) was employed to detect SHED engraftment in the liver. Additionally, real-time PCR and western blotting were used to explore glycogen synthesis, glycolysis and gluconeogenesis in the liver.
At 8 weeks after SHED injection, T2DM was dramatically attenuated, including hyperglycemia, IPGTT and IRT. Additionally, histological analysis showed that SHED injection improved pancreatic islet and liver damage. Real-time PCR analysis showed that SHED significantly reversed the diabetic-induced increase of G-6-Pase, Pck1 and PK; and significantly reversed the diabetic-induced decrease of GSK3β, GLUT2, and PFKL. In addition, western blotting demonstrated that SHED significantly reversed the diabetic-induced increase of G-6-Pase and reversed the diabetic-induced decrease of GLUT2, GSK3β and PFKM.
Stem cells from human exfoliated deciduous teeth offers a potentially effective therapeutic modality for ameliorating T2DM, including hyperglycemia, insulin resistance, pancreatic islets and liver damage, and decreased glycogen synthesis, inhibited glycolysis and increased gluconeogenesis in the liver.
到2030年,糖尿病将成为全球第七大主要死因。2型糖尿病(T2DM)是最常见的糖尿病类型,其特征为胰岛素抵抗和β细胞分泌功能缺陷。人脱落乳牙干细胞(SHED)因其较高的增殖率和更容易获取,是基于间充质干细胞(MSC)治疗的理想种子细胞。目前,尚无研究揭示MSC对Goto-Kakizaki(GK)大鼠T2DM的治疗效果。因此,我们旨在探讨SHED对GK大鼠T2DM的影响。
我们研究了SHED对GK大鼠T2DM进展的影响。通过尾静脉注射SHED和骨髓间充质干细胞(BMSC)。在给药前后测量体重、空腹血糖和非空腹血糖。注射后8周,进行腹腔胰岛素耐量试验(IPITT)和胰岛素释放试验(IRT)。此外,采用苏木精-伊红(HE)染色、过碘酸-希夫(PAS)染色和双标免疫荧光染色来探究胰岛和肝脏的病理变化。采用免疫组织化学(IHC)检测SHED在肝脏中的植入情况。此外,使用实时PCR和蛋白质印迹法来探究肝脏中的糖原合成、糖酵解和糖异生。
SHED注射后8周,T2DM显著减轻,包括高血糖、IPGTT和IRT。此外,组织学分析表明,SHED注射改善了胰岛和肝脏损伤。实时PCR分析表明,SHED显著逆转了糖尿病诱导的G-6-Pase、Pck1和PK的增加;并显著逆转了糖尿病诱导的GSK3β、GLUT2和PFKL的减少。此外,蛋白质印迹法表明,SHED显著逆转了糖尿病诱导的G-6-Pase的增加,并逆转了糖尿病诱导的GLUT2、GSK3β和PFKM的减少。
人脱落乳牙干细胞为改善T2DM提供了一种潜在有效的治疗方式,包括高血糖、胰岛素抵抗、胰岛和肝脏损伤,以及肝脏中糖原合成减少、糖酵解受抑制和糖异生增加。